Cefotiam hydrochloride

J01DC07(WHO) In general: ℞ (Prescription only) (6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-{[1-(2-dimethylaminoethyl)tetrazol-5-yl]sulfanylmethyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 61622-34-2Y 43708 DB00229Y 39831Y 91W6Z2N718 D07648Y CHEBI:355510Y ChEMBL1296Y DTXSID6022763 Interactive​​​‍​​‍​​​​‍​​‍‍ image CN(C)CCN1N=NN=C1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC1=CSC(N)=N1)C2=O)C(O)=O InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1YKey:QYQDKDWGWDOFFU-IUODEOHRSA-NY Cefotiamis aparenteralthird-generationcephalosporinantibiotic. It has broad-spectrum activity againstGram-positiveandGram-negativebacteria. As abeta-lactam, its bactericidal activity results from the inhibition of cell wall synthesis via affinity forpenicillin-binding proteins. It was patented in 1973 and approved for medical use in 1981.